10:13 AM EST - Bausch Health Companies Inc. : And its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24. Bausch Health Companies Inc.
shares T.BHC are trading unchanged at $31.78.
